AGIOS PHARMACEUTICALS, INC. Total Assets

Quick Answer

AGIOS PHARMACEUTICALS, INC. reported Total Assets of $1.30 billion for the year ending 2025.

  • AGIOS PHARMACEUTICALS, INC. showed a decrease of -22.0% in Total Assets from 2024 to 2025.
  • This data is from AGIOS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
  • XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q2 2013: $111.25 million | Q3 2013: $219.07 million | Q1 2014: $181.91 million | Q2 2014: $272.03 million | Q3 2014: $269.61 million | Q1 2015: $474.34 million | Q2 2015: $474.38 million | Q3 2015: $449.09 million | Q1 2016: $396.12 million | Q2 2016: $557.60 million | Q3 2016: $672.04 million | Q1 2017: $557.32 million | Q2 2017: $760.60 million | Q3 2017: $687.20 million | Q1 2018: $1.04 billion | Q2 2018: $998.24 million | Q3 2018: $929.08 million | Q1 2019: $822.13 million | Q2 2019: $783.87 million | Q3 2019: $698.62 million | Q1 2020: $799.74 million | Q2 2020: $976.14 million | Q3 2020: $908.45 million | Q1 2021: $2.49 billion | Q2 2021: $1.87 billion | Q3 2021: $1.54 billion | Q1 2022: $1.34 billion | Q2 2022: $1.25 billion | Q3 2022: $1.18 billion | Q1 2023: $1.15 billion | Q2 2023: $1.09 billion | Q3 2023: $1.01 billion | Q1 2024: $849.71 million | Q2 2024: $773.06 million | Q3 2024: $1.79 billion | Q1 2025: $1.56 billion | Q2 2025: $1.47 billion | Q3 2025: $1.39 billion.
  • Over the full 14 years of available data (2012 to 2025), AGIOS PHARMACEUTICALS, INC.'s Total Assets has grown by 846.8%.
  • Historical annual values: Fiscal year 2025: $1.30 billion | Fiscal year 2024: $1.66 billion | Fiscal year 2023: $937.12 million | Fiscal year 2022: $1.24 billion | Fiscal year 2021: $1.44 billion | Fiscal year 2020: $852.95 million | Fiscal year 2019: $890.74 million | Fiscal year 2018: $858.46 million | Fiscal year 2017: $614.40 million | Fiscal year 2016: $619.09 million | Fiscal year 2015: $420.07 million | Fiscal year 2014: $491.90 million | Fiscal year 2013: $201.21 million | Fiscal year 2012: $137.01 million.
  • Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: